02.20.25 -- January 2025 — CDMO Opportunities And Threats Report

Learn about the rapid growth occurring in the gene and cell therapy industry, driven by technological advancements, an increasing number of development programs, and recent product approvals.

COVID-19 reshaped the pharmaceutical landscape, and its impact on the supply chain is undeniable. As the industry adapts to a new reality, executives are prioritizing reliable, forward-thinking partnerships.

Developers often aim to cut expenses during development. Discover the long-term outcomes of cost-effective measures like using RUO leukopaks compared to investing in high-quality GMP-grade vectors.

Ensure the success of your tech transfer by addressing these key challenges and optimizing your processes for seamless scalability and compliance.

Intensified adherent cell culture offers a promising solution to the limitations of traditional suspension culture, with the potential to improve efficiency, reduce costs, and accelerate development.

Immune cell therapies have incredible potential for cancer treatment, and making them more cost effective is a critical consideration for improving patient access and outcomes.

Explore how TARGATT gene editing and HLA-F technologies are revolutionizing hypoimmunogenic cell development for scalable allogeneic therapies.

Advance your gene therapy program with expert support for IND submission, including GLP toxicology, biodistribution studies, and tailored CMC services.

A new polymer nanoparticle (PNP) system enables targeted delivery of large genetic payloads to neuronal cells, advancing gene therapies for NF1 and other nervous system disorders.

Explore how platform processes advance gene therapies, the impact of strong partnerships on patient access, and the future shaped by these collaborations.

Achieving optimized, scalable suspension processes for adeno-associated virus (AAV)-based therapeutics comes with a number of technical and business challenges.